Clinical Trials
143 trialsNCT02477696 2026-05-27
Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)
Acerta Pharma BV
Phase 3 Active not recruiting
NCT06136559 2026-05-26
BELLWAVE-011
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT02007044 2026-05-20
Ibrutinib With or Without Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT02787369 2026-05-19
ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL
Dana-Farber Cancer Institute
Phase 1 Active not recruiting
NCT01841723 2026-05-13
Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT02160015 2026-05-13
Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT03701282 2026-05-13
Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT01804686 2026-05-08
CAN3001
Janssen Research & Development, LLC
Phase 3 Recruiting
NCT03462719 2026-05-08
GLOW
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT05963074 2026-05-08
TAILOR
Janssen Research & Development, LLC
Phase 2 Recruiting
NCT06299540 2026-05-08
QOLIBRI
Janssen Cilag S.A.S.
Recruiting
NCT06788509 2026-05-08
A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring
Janssen Research & Development, LLC
Phase 1 Enrolling by invitation
NCT05283720 2026-05-06
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
Genmab
Phase 2 Recruiting
NCT01886872 2026-05-04
Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT02048813 2026-05-01
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT03737981 2026-05-01
Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT04608318 2026-04-30
CLL17
German CLL Study Group
Phase 3 Active not recruiting
NCT01500733 2026-04-28
PCI-32765 for Special Cases of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
National Institutes of Health Clinical Center (CC)
Phase 2 Active not recruiting
NCT03479268 2026-04-27
Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma
City of Hope Medical Center
Phase 1 Active not recruiting
NCT05254743 2026-04-20
BRUIN-CLL-314
Eli Lilly and Company
Phase 3 Recruiting
NCT03960840 2026-04-17
Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL
Novartis
Phase 1/2 Active not recruiting
NCT03328078 2026-04-16
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Curis, Inc.
Phase 1/2 Recruiting
NCT02514083 2026-04-14
A Phase II Study Using Ibrutinib and Short-Course Fludarabine in Treatment-Naive CLL
National Institutes of Health Clinical Center (CC)
Phase 2 Active not recruiting
NCT01589302 2026-04-13
PCI-32765 (Ibrutinib) in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-cell Prolymphocytic Leukemia
Ohio State University Comprehensive Cancer Center
Phase 2 Active not recruiting
NCT02518555 2026-04-06
Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Ohio State University Comprehensive Cancer Center
Phase 2 Completed
NCT02537613 2026-04-01
A Study of Ibrutinib + Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Dana-Farber Cancer Institute
Phase 1 Active not recruiting
NCT02629809 2026-03-06
Ibrutinib, Fludarabine Phosphate, Cyclophosphamide, and Obinutuzumab in Treating Patients With Chronic Lymphocytic Leukemia
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT03331198 2026-03-04
Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
Juno Therapeutics, a Subsidiary of Celgene
Phase 1/2 Recruiting
NCT03514017 2026-03-02
Ibrutinib and PD-1 Blockade in High Risk Lymphocytic Leukemia
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Terminated
NCT02756897 2026-02-19
Venetoclax and Ibrutinib in Treating Patients With Chronic or Small Lymphocytic Leukemia
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT02649387 2026-02-10
MERIT
Mayo Clinic
Phase 2 Completed
NCT03513562 2026-02-06
Venetoclax and Ibrutinib in Treating in Participants With Chronic Lymphocytic Leukemia and Ibrutinib Resistance Mutations
Ohio State University Comprehensive Cancer Center
Phase 2 Active not recruiting
NCT03204188 2026-01-30
Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT02427451 2026-01-27
Bcl-2 Inhibitor GDC-0199 in Combination With Obinutuzumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or Previously Untreated Chronic Lymphocytic Leukemia
Ohio State University Comprehensive Cancer Center
Phase 1/2 Active not recruiting
NCT04294641 2026-01-23
Front Line Ibrutinib Without Corticosteroids for Newly Diagnosed Chronic Graft-versus-Host Disease
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT03447808 2026-01-07
Daratumumab and Ibrutinib in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia
Ohio State University Comprehensive Cancer Center
Phase 1 Active not recruiting
NCT03708003 2025-12-30
Ibrutinib lead-in Followed by Venetoclax Plus Ibrutinib in Patients With RR CLL
Swiss Cancer Institute
Phase 2 Terminated
NCT04230304 2025-12-30
Daratumumab and Ibrutinib for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia, DIRECT Study
Mayo Clinic
Phase 2 Terminated
NCT07052695 2025-12-15
Mosunetuzumab for CLL MRD Clearance
Dana-Farber Cancer Institute
Phase 1/2 Recruiting
NCT02666898 2025-11-26
ICLL07GAI
French Innovative Leukemia Organisation
Phase 2 Completed
NCT03734198 2025-11-26
IDA53
French Innovative Leukemia Organisation
Phase 2 Active not recruiting
NCT06958705 2025-11-25
Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor Monotherapy
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Recruiting
NCT03128879 2025-11-21
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT02827617 2025-11-18
Identification of Biomarkers That Are Predictive of Early Ibrutinib Treatment Failure in High Risk TP53 Mutated Chronic Lymphocytic Leukemia
Oncology Institute of Southern Switzerland
Completed
NCT03229200 2025-10-30
Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.
Pharmacyclics Switzerland GmbH
Phase 4 Active not recruiting
NCT02251548 2025-10-24
iFCR
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT05105841 2025-10-15
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
AbbVie
Phase 2 Completed
NCT06520098 2025-10-14
Benefit VA
VA Office of Research and Development
Phase 2 Recruiting
NCT02315768 2025-09-15
Ibrutinib in Combination With GA101 (Obinutuzumab) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients.
University of California, San Diego
Phase 1/2 Completed
NCT03207555 2025-09-02
Ibrutinib as Early Therapy in Chronic Lymphocytic Leukemia (CLL)
M.D. Anderson Cancer Center
Phase 2 Completed